CRISPR Therapeutics public offering: the advisors
CRISPR Therapeutics, a Swiss gene editing company focused on developing transformative gene-based medicines, carried out an underwritten offering of 6,982,143 shares (including overallotment shares), resulting in gross proceeds of approximately USD 520 million. Goldman Sachs & Co. LLC, BofA Securities and Jefferies were acting as joint book-running managers for the offering. Canaccord Genuity, William Blair, SunTrust Robinson Humphrey and Roth Capital Partners were acting as co-managers for the offering. CRISPR is headquartered in Zug, Switzerland. CRISPR’s common shares are listed on Nasdaq.